LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a trailblazer in clinical stage pharmaceutical development, has embarked on a groundbreaking clinical trial in partnership with Roche and the Netherlands Cancer Institute (NKI) to address immune therapy unresponsive metastatic colon cancer. This collaboration focuses on MSI Low metastatic colon cancer, which constitutes approximately 85% of colon […]
Roche and Hitachi High-Tech have announced a significant extension of their partnership, solidifying at least another decade of collaboration in the field of in-vitro diagnostics. This renewal builds on a long-standing relationship that has consistently delivered groundbreaking medical technologies and innovations. Decades of Collaborative Success in Diagnostics Since their initial collaboration in 1978, Roche and […]
Roche has announced positive outcomes from the Phase I clinical trial of CT-388, a novel dual GLP-1/GIP receptor agonist, which is being developed as a once-weekly subcutaneous injection for the treatment of obesity and type 2 diabetes. The trial results revealed significant weight loss and improved glycemic control in participants, positioning CT-388 as a potentially […]
Roche has achieved a significant milestone with the FDA approval of its innovative human papillomavirus (HPV) self-collection solution, positioning it as one of the first such tools available in the United States. This development promises to transform cervical cancer screening by making it more accessible and could play a crucial role in early detection and […]
In a strategic move that significantly escalates its capacity in the biologics manufacturing landscape, Lonza, a key global player in manufacturing for the pharmaceutical, biotech, and nutraceutical markets, announced its acquisition of Genentech’s large-scale biologics manufacturing facility in Vacaville, California, from Roche for USD 1.2 billion. This acquisition marks a significant expansion of Lonza’s manufacturing […]
Roche has announced a definitive agreement to acquire select parts of LumiraDx Group related to its innovative Point of Care technology, a deal totaling $350 million. Expected to close by mid-2024, this acquisition is set to fully integrate the acquired entities into Roche Diagnostics, significantly expanding its diagnostics portfolio. Transforming Point of Care Testing Matt […]
NiKang Therapeutics Inc., a clinical-stage biotech company specializing in small molecule oncology medicines, has announced a significant clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (Roche). This partnership focuses on evaluating NiKang’s NKT2152, a novel small molecule that inhibits hypoxia-inducible factor 2α (HIF2α), in combination with Roche’s atezolizumab (Tecentriq) and bevacizumab (Avastin) […]
Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib (Ibrance) and fulvestrant for treating a specific group of breast cancer patients. The study focuses on individuals with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. […]
Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational therapy inavolisib in combination with palbociclib (Ibrance) and fulvestrant. This study targeted patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The trial met its primary endpoint, showing a significant improvement in […]
Roche announced its definitive agreement to acquire Carmot Therapeutics, Inc., based in Berkeley, California, for an upfront purchase price of USD 2.7 billion, with additional milestone payments of up to USD 400 million. Carmot Therapeutics’ Incretin Portfolio: A Boon for Obesity Treatment The acquisition provides Roche access to Carmot Therapeutics’ innovative portfolio of incretins, which […]
